Asthma Clinical Trials

Find Asthma Clinical Trials Near You

A Multicentre, Randomised, Double-Blind, Parallel-Group Placebo-Controlled, Phase 3, Efficacy and Safety Study of Tezepelumab in 5 to < 12 Year Old Children With Severe Uncontrolled Asthma (HORIZON)

Status: Recruiting
Location: See all (147) locations...
Intervention Type: Biological, Other
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

To assess the efficacy and safety of tezepelumab in pediatric participants with severe uncontrolled asthma on medium to high-dose inhaled corticosteroids (ICS) and at least one additional asthma controller medication with or without oral corticosteroids.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 5
Maximum Age: 11
Healthy Volunteers: f
View:

• Written informed consent from (ICF) at least one parent/caregiver (as per local guidelines) and accompanying informed assent from the participant (where the participant is able to provide assent) prior to admission to the study.

• Participants must be 5 to \< 12 years of age, at the time of signing the assent form (as applicable per local guidelines) and their caregivers signing the ICF and at Visit 3.

• Documented physician diagnosis of severe asthma confirmed and evaluated for at least 6 months prior to Visit 1.

• Documented physician-prescribed treatment with a total daily dose of either medium or high dose, for at least 3 months with stable dose ≥ 1 month prior to Visit 1.

• Documented treatment with at least one additional maintenance asthma controller medication is required according to local guidelines and standard of care; (long-acting beta agonist, leukotriene receptor antagonist, long-acting muscarinic antagonist) for at least 3 months with stable dose ≥ 1 month prior to Visit 1.

• Supportive evidence of asthma as documented by one of the following:

∙ Post-BD (albuterol/salbutamol) responsiveness of FEV1 ≥ 10% during Screening (15 to 30 min after administration of 4 puffs of albuterol/salbutamol with a maximum of 12 puffs of reliever medication only if tolerated by the participant) at either Visit 1 or Visit 2.

∙ If (a) is not achieved at Visit 1 or Visit 2, historical documentation by any of the below prior to Visit 1:

‣ Post-BD responsiveness of FEV1 ≥ 10%.

‣ Positive methacholine challenge defined as provocative concentration (PC20) of ≤ 16 mg/mL.

‣ PEF average daily diurnal variability \> 13% over a 2-week period.

‣ Variability of FEV1 ≥ 12% between any two clinical visits.

‣ Positive exercise challenge test (defined as a fall in FEV1 of \> 12%).

‣ FeNO ≥ 20 ppb despite confirmed ICS maintenance therapy.

• History of at least 2 severe asthma exacerbation events OR 1 severe asthma exacerbation event resulting in hospitalisation within 12 months prior to Visit 1.

• Pre-BD FEV1 \>50% and ≤ 95%PN OR FEV1/forced vital capacity (FVC) ratio ≤ 0.85 at either Visit 1 or Visit 2.

• Evidence of uncontrolled asthma, with at least 1 of the below criteria:

∙ ACQ-IA score ≥ 1.5 at least once during Screening/Run-in, including Visit 3 (prior to Randomisation) for participants ≥ 6 years old at Screening.

‣ Use of reliever medication, other than as a preventive for exercise induced bronchospasm, on 3 or more days per week for at least 1 week during the Screening/Run-in period.

‣ Sleep awakening due to asthma symptoms requiring use of reliever medication at least once during the Screening/Run-in period.

‣ Asthma symptoms 3 or more days per week in at least 1 week during the Screening/Run-in period.

⁃ Body weight ≥ 16 kg at Visit 1 (Screening) and Visit 3 (Randomisation).

Locations
United States
Alabama
Research Site
RECRUITING
Montgomery
Arkansas
Research Site
WITHDRAWN
Little Rock
Arizona
Research Site
RECRUITING
Phoenix
California
Research Site
ACTIVE_NOT_RECRUITING
La Jolla
Research Site
RECRUITING
Long Beach
Research Site
WITHDRAWN
Orange
Research Site
RECRUITING
San Diego
Georgia
Research Site
RECRUITING
Atlanta
Research Site
TERMINATED
Savannah
Massachusetts
Research Site
RECRUITING
Boston
Research Site
RECRUITING
Boston
Maryland
Research Site
RECRUITING
Baltimore
Michigan
Research Site
TERMINATED
Ann Arbor
Research Site
RECRUITING
Detroit
North Carolina
Research Site
RECRUITING
Chapel Hill
New Jersey
Research Site
RECRUITING
Northfield
New York
Research Site
RECRUITING
Hawthorne
Research Site
WITHDRAWN
Schenectady
Research Site
RECRUITING
Staten Island
Ohio
Research Site
RECRUITING
Cincinnati
Research Site
RECRUITING
Cleveland
Research Site
RECRUITING
Toledo
Oklahoma
Research Site
RECRUITING
Oklahoma City
South Carolina
Research Site
WITHDRAWN
Columbia
Texas
Research Site
TERMINATED
Coppell
Research Site
RECRUITING
Dallas
Research Site
WITHDRAWN
Frisco
Research Site
RECRUITING
Houston
Research Site
RECRUITING
San Antonio
Research Site
WITHDRAWN
Temple
Other Locations
Argentina
Research Site
RECRUITING
Buenos Aires
Research Site
RECRUITING
Buenos Aires
Research Site
RECRUITING
Buenos Aires
Research Site
TERMINATED
Caba
Research Site
RECRUITING
Florida
Research Site
RECRUITING
Lanus
Research Site
RECRUITING
Lobos
Research Site
RECRUITING
Mendoza
Research Site
TERMINATED
Quilmes
Research Site
RECRUITING
Rosario
Brazil
Research Site
RECRUITING
Blumenau
Research Site
RECRUITING
Curitiba
Research Site
WITHDRAWN
Salvador
Research Site
RECRUITING
São Paulo
Research Site
RECRUITING
São Paulo
Research Site
ACTIVE_NOT_RECRUITING
São Paulo
Research Site
RECRUITING
Sorocaba
Canada
Research Site
RECRUITING
Burlington
Research Site
RECRUITING
Edmonton
Research Site
RECRUITING
Hamilton
Research Site
RECRUITING
Montreal
Research Site
RECRUITING
Windsor
China
Research Site
RECRUITING
Beijing
Research Site
RECRUITING
Changchun
Research Site
RECRUITING
Hohhot
Research Site
RECRUITING
Lanzhou
Research Site
RECRUITING
Nanjing
Research Site
WITHDRAWN
Shanghai
Research Site
RECRUITING
Shanghai
Research Site
RECRUITING
Shenyang
Research Site
RECRUITING
Shenzhen
Research Site
NOT_YET_RECRUITING
Tianjin
Research Site
RECRUITING
Wuxi
Research Site
NOT_YET_RECRUITING
Zhanjiang
Research Site
NOT_YET_RECRUITING
Zhongshan
Colombia
Research Site
WITHDRAWN
Bogotá
Research Site
WITHDRAWN
Bogotá
Research Site
WITHDRAWN
Medellín
France
Research Site
RECRUITING
Brest
Research Site
SUSPENDED
Bron
Research Site
RECRUITING
Créteil
Research Site
RECRUITING
Marseille
Research Site
RECRUITING
Paris
Research Site
RECRUITING
Paris
Research Site
RECRUITING
Paris
Research Site
RECRUITING
Rouen
Research Site
RECRUITING
Vandœuvre-lès-nancy
Hungary
Research Site
COMPLETED
Debrecen
Research Site
RECRUITING
Szeged
Research Site
RECRUITING
Szigetvár
Italy
Research Site
RECRUITING
Genova
Research Site
RECRUITING
Pavia
Research Site
RECRUITING
Roma
Japan
Research Site
RECRUITING
Fukuoka
Research Site
RECRUITING
Fukuoka
Research Site
RECRUITING
Fukuyama
Research Site
RECRUITING
Funabashi-shi
Research Site
RECRUITING
Nara
Research Site
RECRUITING
Odawara
Research Site
RECRUITING
Ōtsu
Research Site
RECRUITING
Saga
Research Site
RECRUITING
Shimotsuga-gun
Research Site
WITHDRAWN
Yokohama
Mexico
Research Site
RECRUITING
Chihuahua City
Research Site
RECRUITING
Guadalajara
Research Site
NOT_YET_RECRUITING
Mexico City
Research Site
RECRUITING
Veracruz
Netherlands
Research Site
RECRUITING
Amsterdam
Research Site
RECRUITING
Rotterdam
Philippines
Research Site
RECRUITING
Iloilo City
Research Site
RECRUITING
Las Piñas
Research Site
RECRUITING
Quezon
Research Site
RECRUITING
Santa Rosa
Poland
Research Site
RECRUITING
Lodz
Research Site
RECRUITING
Tarnów
Republic of Korea
Research Site
WITHDRAWN
Seongnam-si
Research Site
RECRUITING
Seongnam-si
Research Site
RECRUITING
Seoul
Research Site
RECRUITING
Seoul
Romania
Research Site
RECRUITING
Bucharest
Research Site
RECRUITING
Bucharest
South Africa
Research Site
RECRUITING
Bellville
Research Site
RECRUITING
Cape Town
Research Site
RECRUITING
Durban
Research Site
ACTIVE_NOT_RECRUITING
Durban
Research Site
RECRUITING
Middelburg
Research Site
WITHDRAWN
Thabazimbi
Research Site
RECRUITING
Vereeniging
Research Site
RECRUITING
Welkom
Spain
Research Site
RECRUITING
Badalona
Research Site
RECRUITING
Barcelona
Research Site
RECRUITING
Esplugues De Llobregat (barc)
Research Site
RECRUITING
Madrid
Research Site
RECRUITING
Sabadell
Research Site
WITHDRAWN
Valencia
Research Site
RECRUITING
Valencia
Research Site
RECRUITING
Villarreal
Thailand
Research Site
RECRUITING
Bangkok
Research Site
RECRUITING
Bangkoknoi
Research Site
RECRUITING
Chiang Mai
Research Site
RECRUITING
Muang
Turkey
Research Site
RECRUITING
Bursa
Research Site
RECRUITING
Istanbul
Research Site
RECRUITING
Izmir
Research Site
RECRUITING
Yenimahalle
Ukraine
Research Site
RECRUITING
Chernivtsi
Research Site
RECRUITING
Ivano-frankivsk
Research Site
RECRUITING
Kyiv
Research Site
RECRUITING
Kyiv
United Kingdom
Research Site
RECRUITING
Birmingham
Research Site
RECRUITING
Bradford
Research Site
RECRUITING
Bristol
Research Site
WITHDRAWN
Glasgow
Research Site
RECRUITING
Leicester
Research Site
RECRUITING
London
Research Site
RECRUITING
Nottingham
Research Site
RECRUITING
Stoke-on-trent
Contact Information
Primary
AstraZeneca Clinical Study Information Center
information.center@astrazeneca.com
1-877-240-9479
Time Frame
Start Date: 2023-08-24
Estimated Completion Date: 2030-08-23
Participants
Target number of participants: 231
Treatments
Experimental: Tezepelumab
Participants will be receiving tezepelumab subcutaneous injection
Placebo_comparator: Placebo
Participants will be receiving placebo through a subcutaneous injection
Related Therapeutic Areas
Sponsors
Leads: AstraZeneca
Collaborators: Amgen

This content was sourced from clinicaltrials.gov